Opdivo winning the PD-1 War







It's going to be fun watching the Oncology group crash. Inferior product, inflated egos, inflated salaries and not much genuine talent. It's a recipe for entertainment.
There is not a group within the industry that compares to us. You have a poor education unfit for real science background and experience. We get paid for our results not for serving lunches!
 


















3Q 2015 Opdivo vs. Keytruda Results are in!

Opdivo: From BMS website: Third Quarter 2015 Financial Results Press Release

Three months ended 9/30/15: Worldwide- $305M U.S. $268M

Keytruda: From Merck website: Third Quarter 2015 Financial Results Press Release
Approximately $160M (Global)

Supplement to 3Q 2015 Earnings Release
U.S. Sales $109M


GAME OVER!
 






3Q 2015 Opdivo vs. Keytruda Results are in!

Opdivo: From BMS website: Third Quarter 2015 Financial Results Press Release

Three months ended 9/30/15: Worldwide- $305M U.S. $268M

Keytruda: From Merck website: Third Quarter 2015 Financial Results Press Release
Approximately $160M (Global)

Supplement to 3Q 2015 Earnings Release
U.S. Sales $109M


GAME OVER!
It's going to get a LOT more lopsided than that!
 




































I have the largest sales in the nation and out selling the competing three to one. Very easy to exceed just get out of bed call on the three most influential practitioners every week and present appropriate inducements. The remaining weekly time is all mine!
 
























I have the largest sales in the nation and out selling the competing three to one. Very easy to exceed just get out of bed call on the three most influential practitioners every week and present appropriate inducements. The remaining weekly time is all mine!
The colon rectal data just placed us on protocol at the cancer center
 






"As it stands, analysts expect Opdivo to lead the pack with about $8.8 billion in sales by 2020, followed by Keytruda at $5.5 billion. But there are many trials, approvals and labels to be revealed in the intervening years that could change the landscape."

$5.5 Billion would not be too bad. Big market, nice share.
Not like the fatalistic rants here.
 






"As it stands, analysts expect Opdivo to lead the pack with about $8.8 billion in sales by 2020, followed by Keytruda at $5.5 billion. But there are many trials, approvals and labels to be revealed in the intervening years that could change the landscape."

$5.5 Billion would not be too bad. Big market, nice share.
Not like the fatalistic rants here.

BMS aka Batman
MRK aka Robin
 






I have the largest sales in the nation and out selling the competing three to one. Very easy to exceed just get out of bed call on the three most influential practitioners every week and present appropriate inducements. The remaining weekly time is all mine!
The golf outing at Sawgrass brought out all the important players and fun had by all. Sales will skyrocket!